Nanoenzalutamide is expected to progress via the ANDA*/Hybrid generic pathway and as such will need to show ... ANDA=Abbreviated New Drug Application The global annual sales of Xtandi® is presently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback